Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey
[...]question remains of whether the adoption of these still largely unapproved regimens for locoregional melanoma metastases into routine clinical practice is justified. [...]melanoma experts nominated by the Melanoma World Society (MWS) and the European Association of Dermato-Oncology (EADO) were...
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2025-01, Vol.26 (1), p.12-14 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 1 |
| container_start_page | 12 |
| container_title | The lancet oncology |
| container_volume | 26 |
| creator | Hauschild, Axel Garbe, Claus Ascierto, Paolo Antonio Demidov, Lev Dreno, Brigitte Dummer, Reinhard Eggermont, Alexander Forsea, Ana-Maria Gebhardt, Christoffer Gershenwald, Jeffrey E Hamid, Omid Hoeller, Christoph Kandolf, Lidija Kaufmann, Roland Kirkwood, John M Lebbé, Celeste Long, Georgina V Malvehy, Josep Martin-Algarra, Salvador McArthur, Grant Neyns, Bart Richtig, Erika Robert, Caroline Schadendorf, Dirk Scolyer, Richard Sondak, Vernon K Wainstein, Alberto Weichenthal, Michael Nuti, Paolo |
| description | [...]question remains of whether the adoption of these still largely unapproved regimens for locoregional melanoma metastases into routine clinical practice is justified. [...]melanoma experts nominated by the Melanoma World Society (MWS) and the European Association of Dermato-Oncology (EADO) were surveyed about their opinions and experiences regarding the use of these new therapies for melanoma with locoregional metastasis. [...]the question of which schedule should be introduced first into practice was also answered in favour of the SWOG S1801 schedule (56 [54%] of 104 respondents vs 11 [10%] of 104 respondents for the NADINA or OpACINneo schedule). [...]regarding the approval of neoadjuvant therapies in their countries, 86 (83%) of 104 experts expected the SWOG 1801 regimen to be approved and reimbursed in the next 3 years, while only 52 (50%) of 104 experts foresaw the same for the NADINA or OpACINneo regimen. [...]all experts consider both therapies to be safe enough for patients with resectable locoregional disease (AJCC stage III disease). |
| doi_str_mv | 10.1016/S1470-2045(24)00627-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04870715v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3151040828</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1640-5bb9b5e85c2b0915548fbcdc6066104f54d1af58d37034571b47fd140479d8e83</originalsourceid><addsrcrecordid>eNpdkcFu1DAQhi0EoqXlEUCRuLSH0JlkHDvcqgoo0ooeoGfLcRzVqyQOdrLSvj3OpvSAZNm_Zr6Z8ehn7APCZwSsbn4hCcgLIH5V0DVAVYi8eMXOU5hyTlK-PukNOWPvYtwDoEDgb9lZWQteEcE52_-0Xrf75aDHOfMhm2xwPl16dgebzU9JTcesS5nB9nr0g05i1jEdFzM3ZqZ3ozO6z6agzeyM_ZLpMSVmG8bUxI8pFZdwsMdL9qbTfbTvn98L9vjt6--7-3z38P3H3e0uN1gR5Lxp6oZbyU3RQI087dI1pjUVVBUCdZxa1B2XbSmgJC6wIdG1SECibqWV5QW73vo-6V5NwQ06HJXXTt3f7tQaA5ICBPIDJvZqY6fg_yw2zmpw0dg-rWr9ElWJHKWoqF7RT_-he7-kHfuNAgJZrMP5RpngYwy2e_kBglqNUyfj1OqKKkidjFNFqvv43H1pBtu-VP1zqvwLHhiS-g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3151040828</pqid></control><display><type>article</type><title>Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Hauschild, Axel ; Garbe, Claus ; Ascierto, Paolo Antonio ; Demidov, Lev ; Dreno, Brigitte ; Dummer, Reinhard ; Eggermont, Alexander ; Forsea, Ana-Maria ; Gebhardt, Christoffer ; Gershenwald, Jeffrey E ; Hamid, Omid ; Hoeller, Christoph ; Kandolf, Lidija ; Kaufmann, Roland ; Kirkwood, John M ; Lebbé, Celeste ; Long, Georgina V ; Malvehy, Josep ; Martin-Algarra, Salvador ; McArthur, Grant ; Neyns, Bart ; Richtig, Erika ; Robert, Caroline ; Schadendorf, Dirk ; Scolyer, Richard ; Sondak, Vernon K ; Wainstein, Alberto ; Weichenthal, Michael ; Nuti, Paolo</creator><creatorcontrib>Hauschild, Axel ; Garbe, Claus ; Ascierto, Paolo Antonio ; Demidov, Lev ; Dreno, Brigitte ; Dummer, Reinhard ; Eggermont, Alexander ; Forsea, Ana-Maria ; Gebhardt, Christoffer ; Gershenwald, Jeffrey E ; Hamid, Omid ; Hoeller, Christoph ; Kandolf, Lidija ; Kaufmann, Roland ; Kirkwood, John M ; Lebbé, Celeste ; Long, Georgina V ; Malvehy, Josep ; Martin-Algarra, Salvador ; McArthur, Grant ; Neyns, Bart ; Richtig, Erika ; Robert, Caroline ; Schadendorf, Dirk ; Scolyer, Richard ; Sondak, Vernon K ; Wainstein, Alberto ; Weichenthal, Michael ; Nuti, Paolo ; Melanoma World Society Study Group</creatorcontrib><description>[...]question remains of whether the adoption of these still largely unapproved regimens for locoregional melanoma metastases into routine clinical practice is justified. [...]melanoma experts nominated by the Melanoma World Society (MWS) and the European Association of Dermato-Oncology (EADO) were surveyed about their opinions and experiences regarding the use of these new therapies for melanoma with locoregional metastasis. [...]the question of which schedule should be introduced first into practice was also answered in favour of the SWOG S1801 schedule (56 [54%] of 104 respondents vs 11 [10%] of 104 respondents for the NADINA or OpACINneo schedule). [...]regarding the approval of neoadjuvant therapies in their countries, 86 (83%) of 104 experts expected the SWOG 1801 regimen to be approved and reimbursed in the next 3 years, while only 52 (50%) of 104 experts foresaw the same for the NADINA or OpACINneo regimen. [...]all experts consider both therapies to be safe enough for patients with resectable locoregional disease (AJCC stage III disease).</description><identifier>ISSN: 1470-2045</identifier><identifier>ISSN: 1474-5488</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(24)00627-2</identifier><identifier>PMID: 39756440</identifier><language>eng</language><publisher>England: Elsevier Limited</publisher><subject>Cancer therapies ; Clinical medicine ; Committees ; FDA approval ; Immunotherapy ; Life Sciences ; Melanoma ; Metastases ; Metastasis ; Oncology ; Participation ; Polls & surveys ; Reimbursement ; Roles ; Scandals ; Schedules ; Skin cancer ; Surgery</subject><ispartof>The lancet oncology, 2025-01, Vol.26 (1), p.12-14</ispartof><rights>2025. Elsevier Ltd</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1640-5bb9b5e85c2b0915548fbcdc6066104f54d1af58d37034571b47fd140479d8e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39756440$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://nantes-universite.hal.science/hal-04870715$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Hauschild, Axel</creatorcontrib><creatorcontrib>Garbe, Claus</creatorcontrib><creatorcontrib>Ascierto, Paolo Antonio</creatorcontrib><creatorcontrib>Demidov, Lev</creatorcontrib><creatorcontrib>Dreno, Brigitte</creatorcontrib><creatorcontrib>Dummer, Reinhard</creatorcontrib><creatorcontrib>Eggermont, Alexander</creatorcontrib><creatorcontrib>Forsea, Ana-Maria</creatorcontrib><creatorcontrib>Gebhardt, Christoffer</creatorcontrib><creatorcontrib>Gershenwald, Jeffrey E</creatorcontrib><creatorcontrib>Hamid, Omid</creatorcontrib><creatorcontrib>Hoeller, Christoph</creatorcontrib><creatorcontrib>Kandolf, Lidija</creatorcontrib><creatorcontrib>Kaufmann, Roland</creatorcontrib><creatorcontrib>Kirkwood, John M</creatorcontrib><creatorcontrib>Lebbé, Celeste</creatorcontrib><creatorcontrib>Long, Georgina V</creatorcontrib><creatorcontrib>Malvehy, Josep</creatorcontrib><creatorcontrib>Martin-Algarra, Salvador</creatorcontrib><creatorcontrib>McArthur, Grant</creatorcontrib><creatorcontrib>Neyns, Bart</creatorcontrib><creatorcontrib>Richtig, Erika</creatorcontrib><creatorcontrib>Robert, Caroline</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><creatorcontrib>Scolyer, Richard</creatorcontrib><creatorcontrib>Sondak, Vernon K</creatorcontrib><creatorcontrib>Wainstein, Alberto</creatorcontrib><creatorcontrib>Weichenthal, Michael</creatorcontrib><creatorcontrib>Nuti, Paolo</creatorcontrib><creatorcontrib>Melanoma World Society Study Group</creatorcontrib><title>Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>[...]question remains of whether the adoption of these still largely unapproved regimens for locoregional melanoma metastases into routine clinical practice is justified. [...]melanoma experts nominated by the Melanoma World Society (MWS) and the European Association of Dermato-Oncology (EADO) were surveyed about their opinions and experiences regarding the use of these new therapies for melanoma with locoregional metastasis. [...]the question of which schedule should be introduced first into practice was also answered in favour of the SWOG S1801 schedule (56 [54%] of 104 respondents vs 11 [10%] of 104 respondents for the NADINA or OpACINneo schedule). [...]regarding the approval of neoadjuvant therapies in their countries, 86 (83%) of 104 experts expected the SWOG 1801 regimen to be approved and reimbursed in the next 3 years, while only 52 (50%) of 104 experts foresaw the same for the NADINA or OpACINneo regimen. [...]all experts consider both therapies to be safe enough for patients with resectable locoregional disease (AJCC stage III disease).</description><subject>Cancer therapies</subject><subject>Clinical medicine</subject><subject>Committees</subject><subject>FDA approval</subject><subject>Immunotherapy</subject><subject>Life Sciences</subject><subject>Melanoma</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Participation</subject><subject>Polls & surveys</subject><subject>Reimbursement</subject><subject>Roles</subject><subject>Scandals</subject><subject>Schedules</subject><subject>Skin cancer</subject><subject>Surgery</subject><issn>1470-2045</issn><issn>1474-5488</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNpdkcFu1DAQhi0EoqXlEUCRuLSH0JlkHDvcqgoo0ooeoGfLcRzVqyQOdrLSvj3OpvSAZNm_Zr6Z8ehn7APCZwSsbn4hCcgLIH5V0DVAVYi8eMXOU5hyTlK-PukNOWPvYtwDoEDgb9lZWQteEcE52_-0Xrf75aDHOfMhm2xwPl16dgebzU9JTcesS5nB9nr0g05i1jEdFzM3ZqZ3ozO6z6agzeyM_ZLpMSVmG8bUxI8pFZdwsMdL9qbTfbTvn98L9vjt6--7-3z38P3H3e0uN1gR5Lxp6oZbyU3RQI087dI1pjUVVBUCdZxa1B2XbSmgJC6wIdG1SECibqWV5QW73vo-6V5NwQ06HJXXTt3f7tQaA5ICBPIDJvZqY6fg_yw2zmpw0dg-rWr9ElWJHKWoqF7RT_-he7-kHfuNAgJZrMP5RpngYwy2e_kBglqNUyfj1OqKKkidjFNFqvv43H1pBtu-VP1zqvwLHhiS-g</recordid><startdate>202501</startdate><enddate>202501</enddate><creator>Hauschild, Axel</creator><creator>Garbe, Claus</creator><creator>Ascierto, Paolo Antonio</creator><creator>Demidov, Lev</creator><creator>Dreno, Brigitte</creator><creator>Dummer, Reinhard</creator><creator>Eggermont, Alexander</creator><creator>Forsea, Ana-Maria</creator><creator>Gebhardt, Christoffer</creator><creator>Gershenwald, Jeffrey E</creator><creator>Hamid, Omid</creator><creator>Hoeller, Christoph</creator><creator>Kandolf, Lidija</creator><creator>Kaufmann, Roland</creator><creator>Kirkwood, John M</creator><creator>Lebbé, Celeste</creator><creator>Long, Georgina V</creator><creator>Malvehy, Josep</creator><creator>Martin-Algarra, Salvador</creator><creator>McArthur, Grant</creator><creator>Neyns, Bart</creator><creator>Richtig, Erika</creator><creator>Robert, Caroline</creator><creator>Schadendorf, Dirk</creator><creator>Scolyer, Richard</creator><creator>Sondak, Vernon K</creator><creator>Wainstein, Alberto</creator><creator>Weichenthal, Michael</creator><creator>Nuti, Paolo</creator><general>Elsevier Limited</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>202501</creationdate><title>Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey</title><author>Hauschild, Axel ; Garbe, Claus ; Ascierto, Paolo Antonio ; Demidov, Lev ; Dreno, Brigitte ; Dummer, Reinhard ; Eggermont, Alexander ; Forsea, Ana-Maria ; Gebhardt, Christoffer ; Gershenwald, Jeffrey E ; Hamid, Omid ; Hoeller, Christoph ; Kandolf, Lidija ; Kaufmann, Roland ; Kirkwood, John M ; Lebbé, Celeste ; Long, Georgina V ; Malvehy, Josep ; Martin-Algarra, Salvador ; McArthur, Grant ; Neyns, Bart ; Richtig, Erika ; Robert, Caroline ; Schadendorf, Dirk ; Scolyer, Richard ; Sondak, Vernon K ; Wainstein, Alberto ; Weichenthal, Michael ; Nuti, Paolo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1640-5bb9b5e85c2b0915548fbcdc6066104f54d1af58d37034571b47fd140479d8e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Cancer therapies</topic><topic>Clinical medicine</topic><topic>Committees</topic><topic>FDA approval</topic><topic>Immunotherapy</topic><topic>Life Sciences</topic><topic>Melanoma</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Participation</topic><topic>Polls & surveys</topic><topic>Reimbursement</topic><topic>Roles</topic><topic>Scandals</topic><topic>Schedules</topic><topic>Skin cancer</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hauschild, Axel</creatorcontrib><creatorcontrib>Garbe, Claus</creatorcontrib><creatorcontrib>Ascierto, Paolo Antonio</creatorcontrib><creatorcontrib>Demidov, Lev</creatorcontrib><creatorcontrib>Dreno, Brigitte</creatorcontrib><creatorcontrib>Dummer, Reinhard</creatorcontrib><creatorcontrib>Eggermont, Alexander</creatorcontrib><creatorcontrib>Forsea, Ana-Maria</creatorcontrib><creatorcontrib>Gebhardt, Christoffer</creatorcontrib><creatorcontrib>Gershenwald, Jeffrey E</creatorcontrib><creatorcontrib>Hamid, Omid</creatorcontrib><creatorcontrib>Hoeller, Christoph</creatorcontrib><creatorcontrib>Kandolf, Lidija</creatorcontrib><creatorcontrib>Kaufmann, Roland</creatorcontrib><creatorcontrib>Kirkwood, John M</creatorcontrib><creatorcontrib>Lebbé, Celeste</creatorcontrib><creatorcontrib>Long, Georgina V</creatorcontrib><creatorcontrib>Malvehy, Josep</creatorcontrib><creatorcontrib>Martin-Algarra, Salvador</creatorcontrib><creatorcontrib>McArthur, Grant</creatorcontrib><creatorcontrib>Neyns, Bart</creatorcontrib><creatorcontrib>Richtig, Erika</creatorcontrib><creatorcontrib>Robert, Caroline</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><creatorcontrib>Scolyer, Richard</creatorcontrib><creatorcontrib>Sondak, Vernon K</creatorcontrib><creatorcontrib>Wainstein, Alberto</creatorcontrib><creatorcontrib>Weichenthal, Michael</creatorcontrib><creatorcontrib>Nuti, Paolo</creatorcontrib><creatorcontrib>Melanoma World Society Study Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hauschild, Axel</au><au>Garbe, Claus</au><au>Ascierto, Paolo Antonio</au><au>Demidov, Lev</au><au>Dreno, Brigitte</au><au>Dummer, Reinhard</au><au>Eggermont, Alexander</au><au>Forsea, Ana-Maria</au><au>Gebhardt, Christoffer</au><au>Gershenwald, Jeffrey E</au><au>Hamid, Omid</au><au>Hoeller, Christoph</au><au>Kandolf, Lidija</au><au>Kaufmann, Roland</au><au>Kirkwood, John M</au><au>Lebbé, Celeste</au><au>Long, Georgina V</au><au>Malvehy, Josep</au><au>Martin-Algarra, Salvador</au><au>McArthur, Grant</au><au>Neyns, Bart</au><au>Richtig, Erika</au><au>Robert, Caroline</au><au>Schadendorf, Dirk</au><au>Scolyer, Richard</au><au>Sondak, Vernon K</au><au>Wainstein, Alberto</au><au>Weichenthal, Michael</au><au>Nuti, Paolo</au><aucorp>Melanoma World Society Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2025-01</date><risdate>2025</risdate><volume>26</volume><issue>1</issue><spage>12</spage><epage>14</epage><pages>12-14</pages><issn>1470-2045</issn><issn>1474-5488</issn><eissn>1474-5488</eissn><abstract>[...]question remains of whether the adoption of these still largely unapproved regimens for locoregional melanoma metastases into routine clinical practice is justified. [...]melanoma experts nominated by the Melanoma World Society (MWS) and the European Association of Dermato-Oncology (EADO) were surveyed about their opinions and experiences regarding the use of these new therapies for melanoma with locoregional metastasis. [...]the question of which schedule should be introduced first into practice was also answered in favour of the SWOG S1801 schedule (56 [54%] of 104 respondents vs 11 [10%] of 104 respondents for the NADINA or OpACINneo schedule). [...]regarding the approval of neoadjuvant therapies in their countries, 86 (83%) of 104 experts expected the SWOG 1801 regimen to be approved and reimbursed in the next 3 years, while only 52 (50%) of 104 experts foresaw the same for the NADINA or OpACINneo regimen. [...]all experts consider both therapies to be safe enough for patients with resectable locoregional disease (AJCC stage III disease).</abstract><cop>England</cop><pub>Elsevier Limited</pub><pmid>39756440</pmid><doi>10.1016/S1470-2045(24)00627-2</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2025-01, Vol.26 (1), p.12-14 |
| issn | 1470-2045 1474-5488 1474-5488 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04870715v1 |
| source | ScienceDirect Journals (5 years ago - present) |
| subjects | Cancer therapies Clinical medicine Committees FDA approval Immunotherapy Life Sciences Melanoma Metastases Metastasis Oncology Participation Polls & surveys Reimbursement Roles Scandals Schedules Skin cancer Surgery |
| title | Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T01%3A46%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neoadjuvant%20or%20perioperative%20therapy%20for%20melanoma%20metastasis%20in%20clinical%20practice:%20an%20international%20survey&rft.jtitle=The%20lancet%20oncology&rft.au=Hauschild,%20Axel&rft.aucorp=Melanoma%20World%20Society%20Study%20Group&rft.date=2025-01&rft.volume=26&rft.issue=1&rft.spage=12&rft.epage=14&rft.pages=12-14&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(24)00627-2&rft_dat=%3Cproquest_hal_p%3E3151040828%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3151040828&rft_id=info:pmid/39756440&rfr_iscdi=true |